Keywords
Treatment
Management
How to Cite
Abstract
Introduction: Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects the motor cells of the brain and spinal cord, leading to the gradual loss of muscle function and disability in patients. Given the complexity and multifaceted nature of ALS, its treatment demands an integrated approach, seeking not only the management of physical symptoms, but also emotional and social support, recognizing the importance of patient-centered treatment. Objective: To evaluate the effectiveness of different treatment methods for ALS, highlighting the importance of a multidisciplinary approach in improving patients' quality of life. Methodology: The Cochrane, Scielo and Medline databases were used, searching for articles published between 2022 and 2024, in Portuguese or English. Final Considerations: Integrated approaches in the treatment of Amyotrophic Lateral Sclerosis prove to be essential for improving patients' quality of life, by joining the efforts of professionals from different areas of health. This multidisciplinary strategy allows for more effective symptom management and offers emotional and social support, adapting to individual needs as the disease progresses.
References
ALENCAR, M. A. et al. Fatigue in amyotrophic lateral sclerosis and correlated factors. Arquivos De Neuro-Psiquiatria, v. 80, n. 10, p. 1045–1051, 1 out. 2022.
ALENCAR, M. A. et al. Quality of life, disability, and clinical variables in amyotrophic lateral sclerosis. Arquivos de Neuro-Psiquiatria, v. 80, n. 3, p. 255–261, mar. 2022.
BONGIOANNI, P. et al. Methods for informing people with amyotrophic lateral sclerosis/motor neuron disease of their diagnosis. Cochrane Database Syst Rev, p. CD007593–CD007593, 2023.
CARVALHO, M. DE. Diagnostic track in amyotrophic lateral sclerosis: the Brazilian experience. Arquivos de Neuro-Psiquiatria, v. 80, n. 07, p. 661–662, jul. 2022.
KATO, H. et al. Effect of Serum Perampanel Concentration on Sporadic Amyotrophic Lateral Sclerosis Progression. Journal of Clinical Neurology, v. 19, n. 3, p. 280–280, 1 jan. 2023.
LEONARD et al. Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study. The Lancet Neurology, 1 jul. 2024.
LI, X. et al. Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis. Journal of Clinical Neuromuscular Disease, v. 24, n. 4, p. 214–221, 23 maio 2023.
LIU, M. et al. A multicenter, randomized, double blind, placebo-controlled clinical trial of DL-3-n-butylphthalide in treatment of amyotrophic lateral sclerosis. Chinese Medical Journal, v. 136, n. 3, p. 354–356, 5 fev. 2023.
MCGRATH, M. S. et al. Regulation of the Innate Immune System as a Therapeutic Approach to Supporting Respiratory Function in ALS. Cells, v. 12, n. 7, p. 1031, 28 mar. 2023.
SCHUSTER, J. et al. In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis. Eur J Neurol, p. e16204–e16204, 2024.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Priscylla Lucena Santos, Bianca Almeida Pessoa Rodrigues de Araújo, Aliandro Willy Duarte Magalhães, Roberto Tavares Carreiro, Denise dos Santos Moitinho, Franciely Gustavo Rodrigues Colpani, Déborah Figueira da Costa, João Pedro de Assis Ferrari, Leandro Aparecido Irrazabal, Caio Fernando Lima Ribeiro, Breno Garcia Aguiar, Tainá Riqueli Artmann, Victor Matheus Ribeiro Baylão, Alysson Motteran Cândido, Brunno Busnardo Paschoalino